Stock RGMP REGNUM CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Regnum Corp.

Equities

RGMP

US75915R1068

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 20:32:55 16/02/2024 GMT 		5-day change 1st Jan Change
0.0001 USD -98.31% Intraday chart for Regnum Corp. -.--% -98.31%
2023 Regnum Corp. Announces Resignation of Anne Kirby as Chief Executive Officer CI
2023 Regnum Corp. Announces Resignation of Anne Kirby as Sole Member of Board of Directors CI

Valuation

Fiscal Period: December 2019 2020 2021 2022
Capitalization 1 1.951 5.988 3.47 3.098
Enterprise Value (EV) 1 1.943 5.988 3.492 3.871
P/E ratio -53.6 x -50.4 x -13 x -3.97 x
Yield - - - -
Capitalization / Revenue 310 x 665 x - -
EV / Revenue 308 x 665 x - -
EV / EBITDA -55.2 x -53.1 x -9.61 x -
EV / FCF -75,588,549 x 163,222,746 x 199,138,914 x -9,011,277 x
FCF Yield -0% 0% 0% -0%
Price to Book 254 x -119 x -9.14 x -2.67 x
Nbr of stocks (in thousands) 22,950 23,950 22,950 22,950
Reference price 2 0.0850 0.2500 0.1512 0.1350
Announcement Date 14/04/20 13/08/21 15/04/22 17/04/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 0.0181 0.0214 0.0063 0.009 - -
EBITDA 1 0.00255 0.004045 -0.0352 -0.1129 -0.3636 -
EBIT 1 0.00225 0.003445 -0.0356 -0.1177 -0.3684 -0.7358
Operating Margin 12.43% 16.1% -564.76% -1,307.48% - -
Earnings before Tax (EBT) 1 0.00225 0.003445 -0.0356 -0.1177 -0.2698 -0.7808
Net income 1 0.001387 0.001998 -0.0364 -0.1177 -0.2698 -0.7809
Net margin 7.66% 9.34% -577.46% -1,307.48% - -
EPS 2 0.000112 0.000094 -0.001585 -0.004962 -0.0116 -0.0340
Free Cash Flow - 0.0034 -0.0257 0.0367 0.0175 -0.4296
FCF margin - 15.89% -408.08% 407.59% - -
FCF Conversion (EBITDA) - 84.05% - - - -
FCF Conversion (Net income) - 170.17% - - - -
Dividend per Share - - - - - -
Announcement Date 28/03/18 11/02/19 14/04/20 13/08/21 15/04/22 17/04/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - 0.02 0.77
Net Cash position 1 0.01 0.05 0.01 - - -
Leverage (Debt/EBITDA) - - - - -0.0607 x -
Free Cash Flow - 0 -0.03 0.04 0.02 -0.43
ROE (net income / shareholders' equity) 23.6% 7.06% -141% 551% 125% 101%
ROA (Net income/ Total Assets) - 6.9% -79.2% -1,133% -30.8% -39.1%
Assets 1 - 0.029 0.0459 0.0104 0.8751 1.998
Book Value Per Share 2 0 0 0 -0 -0.0200 -0.0500
Cash Flow per Share 2 0 0 0 - 0.0600 0.0300
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 28/03/18 11/02/19 14/04/20 13/08/21 15/04/22 17/04/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
REGNUM CORP. Stock Regnum Corp.
-98.31% 2.3K
MODERNA, INC. Stock Moderna, Inc.
+67.53% 63.85B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.77% 41.83B
LONZA GROUP AG Stock Lonza Group AG
+45.66% 40.65B
CELLTRION, INC. Stock Celltrion, Inc.
-10.72% 27.12B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.30% 26.52B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.79% 18.69B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.70% 12.73B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.10% 12.11B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.41% 12.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. RGMP Stock
  4. Financials Regnum Corp.